Tadalafil Tablet, Film Coated
Product Images NDC 70518-4549

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70518-4549). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Tadalafil Tablet 5 mg film-coated tablets packaging label showing quantity of 30 tablets. The label includes the NDC number 70518-4549-00, mentions it is prescription only (RX ONLY), and notes it is repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer information for Macleods Pharma USA, Plainsboro, NJ, is also present along with storage instructions.*

FDA Label Image

Fig1 (Tadalafil Figure 1)

A set of four line graphs depicting changes in blood pressure variables over time in hours, comparing Tadalafil to placebo. The graphs show differences in standing systolic and diastolic blood pressure and supine systolic and diastolic blood pressure, with error bars, measured up to 96 hours after administration.*

FDA Label Image

Fig (Tadalafil Figure 2)

A line graph showing the effect of tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure (BP) over 24 hours post-dose. The upper panel depicts standing systolic BP changes, and the lower panel shows supine systolic BP changes, both measured in mmHg over time (hours).*

FDA Label Image

Fig (Tadalafil Figure 3)

A line graph showing the effect of 20 mg tadalafil and placebo, both combined with 8 mg qd doxazosin, on systolic blood pressure (mmHg) over 12 hours. The graph compares measurements at two different times of day, 08:00 and 20:00, indicating variations in blood pressure response over time post-administration.*

FDA Label Image

Fig (Tadalafil Figure 4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The x-axis represents time in hours, and the y-axis represents plasma concentration, illustrating pharmacokinetic profiles for each dosing schedule.*

FDA Label Image

Fig (Tadalafil Figure 5)

A line chart comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil tablets 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change in IPSS score. Tadalafil shows a greater reduction over time compared to placebo.*

FDA Label Image

Fig (Tadalafil Figure 6)

A line graph comparing the change from baseline in IPSS total score over a 12-week duration of treatment between Tadalafil 5 mg tablets and placebo groups. The graph shows two lines indicating improvement in scores, with Tadalafil demonstrating a greater reduction over time, particularly noted at week 4, marked with statistical significance (p<0.01).*

FDA Label Image

Fig (Tadalafil Figure 7)

A line graph showing the least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The vertical axis measures change from baseline, and the horizontal axis represents weeks of therapy at intervals of 0, 4, 12, and 26 weeks. Data points indicate statistically significant differences at weeks 4 and 12.*

FDA Label Image

Fig (Tadalafil Figure 8)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg tablets and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change in IPSS score. Tadalafil shows a greater decrease in score compared to placebo, with statistically significant differences noted.*

FDA Label Image

Stru (Tadalafil Structure)

Chemical structure of tadalafil, showing its specific arrangement of atoms and bonds in a molecular diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.